present clinical trial aimed to evaluate the efficiency of paracetamol
alone and in combination with 3 different nonsteroidal anti-inflammatory
drugs for control of post-endodontic pain.
inclusion criteria were moderate to severe pain of irreversible
pulpitis, by using the Verbal Rating Scale and a 4–10 score on the
Numerical Rating Scale, on anterior or premolar teeth, as well as the
absence of signs and symptoms of apical periodontitis. One hundred
eighty-five trial medications with placebo were prepared, and 170
participants completed the trial. There were 5 groups. P-group received 4
gelatinous capsules of a single dose of paracetamol alone. The IP-group
received similar capsules of a single dose of combined
ibuprofen/paracetamol. MP-group received combined mefenamic
acid/paracetamol, and DP-group received combined diclofenac
K/paracetamol. A Plb-group received doubled gelatinous capsules with no
medications as a single dose, which had the same weight and appearance
as the medicated capsules, to be the placebo.
intensity was measured after initial endodontic therapy and
instrumentation by using the Verbal Rating Scale and Numerical Rating
Scale. IP-group (ibuprofen/paracetamol) had the most pain reduction,
followed by DP-group (combined diclofenac K/paracetamol), then MP-group,
followed by P-group, whereas Plb-group had the least pain reduction (P < .05).
combination of ibuprofen/paracetamol, taken immediately after initial
endodontic therapy and root canal preparation in teeth with irreversible
pulpitis, reduced post-endodontic pain (ClinicalTrials.gov no.: NCT02417337).